Evidence map›Paper›PMID 37886217›Full record

ArticleRespiratory medicine case reports2023

Mepolizumab treatment in a patient with previous liver transplantation: One year follow-up.

Claudio Candia, Francesco Coppa, Lucia Abagnale, Francesco Perna, Antonio Molino

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Claudio CandiaRespiratory Division, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Francesco CoppaRespiratory Division, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Lucia AbagnaleRespiratory Division, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Francesco PernaRespiratory Division, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Antonio MolinoRespiratory Division, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe Asthma (SA) is characterized by inadequate disease control despite maximal inhalation therapy. In November 2021, a 68-years old female patient presented at our facility referring a worsening in her asthma-related symptoms and a high exacerbations rate. She reported a liver transplantation in 2015 and was in treatment with tacrolimus. We started treatment with Mepolizumab 100 mg once every 28 days and monitored her lung function as well as her lymphocytes subsets. After one year follow-up, the patient had a substantial improvement in lung function, exacerbation rate, daily OCS intake dose and no variation in the blood concentration of tacrolimus.

Indexed as

Liver transplantationMepolizumabSevere asthmaTacrolimus

Identifiers

PMID37886217
PMCPMC10598042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.